Introduces a novel biosensor that improves glucose tracking in diabetes management, suggesting enhanced monitoring capabilities.
Continuous glucose monitoring (CGM) is essential for diabetes management. Optical CGM provides a promising approach, yet current existing optical platforms face challenges including phototoxic excitation, shallow tissue penetration, and limited hardware compatibility. Here, we report a visible-light activated implantable nanophotonic biosensor that enables long-term in vivo glucose tracking through dual spectral and biochemical engineering. The sensor leverages Q-band of metalloporphyrins, shifting excitation from the phototoxic near-UV/blue B-band to the safer visible-light region, and couples with a rhodamine via Förster resonance energy transfer (FRET) to achieve efficient photon harvesting, ratiometric calibration, and CMOS-compatible optical readout. To stabilize enzymatic performance and mitigate oxidative damage, a glucose oxidase/catalase (GOx/CAT) cascade rapidly decomposes hydrogen peroxide (H₂O₂) byproducts, preserving sensitivity during extended implantation. This integrated design yields a biocompatible, optically compatible, and long-term stable nanophotonic sensing platform, advancing the development of smart terminal-integrated CGM systems with robust in vivo performance and strong translational potential for personalized diabetes management.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: